Noah Haber


Noah Haber is an interdisciplinary scientist working at the crossroads of causal inference, infectious disease, economics, epidemiology, and meta-science. Dr. Haber’s research integrates two interconnected lines of quantitative research: evaluating the strength of causal inference across the pathway from publication to decision-making, and global HIV/AIDS measurement and evaluation. His methodological roots in health economics and econometrics were developed largely during his doctoral years at the Harvard TH Chan School of Public Health, with additional interdisciplinary studies and collaboration in epidemiology during his prior postdoctoral fellowship at the University of North Carolina and meta-science work at the Meta-Research Innovation Center at Stanford University (METRICS).

Dr. Haber’s causal inference meta-science work focuses on developing methods and systems to more systematically review and understand strength of causal inference and study design across health research, and bridging conceptual gaps between epidemiology and econometrics.


ScD Harvard T.H. Chan School of Public Health
2017 Health Economics, Global Health and Population
Coursework Quantitative methods (econometrics, causal inference, longitudinal/multilevel analysis), Economics (micro, development, behavioral), Global health (HIV/AIDS, population science)
Dissertation Essays on HIV in Rural KwaZulu-Nata, South Africa: Inference from Measurement to Policy
This dissertation  explores the causal impact of threshold rules on HIV recovery, restructuring HIV cascade of care data, and list randomization improve survey elicitation of sensitive behaviors.
Committee Dr. Günther Fink (chair), Dr. Jessica Cohen, Dr. Till Bärnighausen
MSc London School of Economics
2012 International Health Policy: Health Economics, 2011-2012
Coursework Quantitative methods, health systems, health finance, development economics
Thesis “The Viability of RSBY as a Solution for Healthcare Financing for the Poor in India”
BA Brandeis University
2008 Triple major in Economics, Public Health, and Political Science
Thesis “Patent Protection, FDI, and R&D in the Indian Pharmaceutical Industry”


Haber N, Smith ER, Moscoe E, Andrews K, Audy R, Bell W, Brennan AT, Breskin A, Kane JC, Karra M, McClure ES, Suarez EA; CLAIMS research team. Causal language and strength of inference in academic and media articles shared in social media (CLAIMS): A systematic review. PLoS One. 2018 May 30;13(5):e0196346. doi: 10.1371/journal.pone.0196346

Haber N, Harling G, Cohen J, Mutevedzi T, Tanser F, Gareta D, Herbst K, Pillay D, Bärnighausen T, Fink G. List randomization for eliciting HIV status and sexual behaviors in rural KwaZulu-Natal, South Africa: a randomized experiment using known true values for validation. BMC Med Res Methodol. 2018 May 25;18(1):46. doi: 10.1186/s12874-018-0507-9.

Bärnighausen T, Oldenburg C, Tugwell P, Bommer C, Ebert C, Barreto M, Djimeu E, Haber N, Waddington H, Rockers P, Sianesi B, Bor J, Fink G, Valentine J, Tanner J, Stanley T, Sierra E, Tchetgen ET, Atun R, Vollmer S. Quasi-experimental study designs series-paper 7: assessing the assumptions. J Clin Epidemiol. 2017 Sep;89:53-66. doi: 10.1016/j.jclinepi.2017.02.017. Epub 2017 Mar 29. PubMed PMID: 28365306.

Haber N, Tanser F, Bor J, Naidu K, Mutevedzi T, Herbst K, Porter K, Pillay D, Bärnighausen T. From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa. Lancet HIV. 2017 May;4(5):e223-e230. doi: 10.1016/S2352-3018(16)30224-7. Epub 2017 Jan 31. PubMed PMID: 28153470.

Haber N, Pillay D, Porter K, Bärnighausen T. Constructing the cascade of HIV care: methods for measurement. Curr Opin HIV AIDS. 2016 Jan;11(1):102-8. doi: 10.1097/COH.0000000000000212. Review. PubMed PMID: 26545266.

Bor J, Rosen S, Chimbindi N, Haber N, Herbst K, Mutevedzi T, Tanser F, Pillay D, Bärnighausen T. Mass HIV Treatment and Sex Disparities in Life Expectancy: Demographic Surveillance in Rural South Africa. PLoS Med. 2015 Nov 24;12(11):e1001905; discussion e1001905. doi: 10.1371/journal.pmed.1001905. eCollection 2015 Nov. PubMed PMID: 26599699; PubMed Central PMCID: PMC4658174.

Ward A, Quon P, Abouzaid S, Haber N, Ahmed S, Kim E. Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluation. P T. 2013 Feb;38(2):109-15. PubMed PMID: 23599678; PubMed Central PMCID: PMC3628175.

Kwong WJ, Ozer-Stillman I, Miller JD, Haber NA, Russell MW, Kavanagh S. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain. Clin Ther. 2010 Sep;32(10):1768-81. doi: 10.1016/j.clinthera.2010.09.011. PubMed PMID: 21194601.


Postdoctoral research Carolina Population Center, University of North Carolina, April 2017 – present
  Postdoctoral trainee. Preceptor: Dr. Audrey Pettifor
Funding: T32 NICHD-NRSA
Teaching Econometrics for Health Policy (GHP 525), Fall 2014 and 2015
Teaching assistant. Head faculty: Dr. Günther Fink
Econometric Methods in Impact Evaluation (GHP 228), Spring 2014 and 2015
Teaching assistant. Head faculty: Dr. Jessica Cohen
Health Economics with Applications to Global Health Policy (HPM 260), Summer 2016
Teaching assistant. Head faculty: Dr. Meredith Rosenthal
Professional United BioSource Corporation / Abt BioPharma Solutions, May 2008 – August 2011
Research Associate. Part of a small team which designs and builds health-economic models to determine the cost-effectiveness and / or budgetary impact related to pharmaceuticals in numerous disease areas.